Pierre-Antoine Moulin1, Anne Dutour2, Patricia Ancel2, Pierre-Emmanuel Morange3, Thierry Bege4, Olivier Ziegler5, Stéphane Berdah4, Corinne Frère1, Bénédicte Gaborit6. 1. Hematology Department, Hôpital de la Timone, APHM, Aix-Marseille Université, Marseille, France. 2. Endocrinology, Metabolic Diseases, and Nutrition Department, Pole ENDO, APHM, Aix-Marseille Université, Marseille, France; Centre Spécialisé de l'Obésité (CSO) PACA Ouest, France; Aix Marseille Univ, INSERM, INRA, NORT, Marseille, France. 3. Hematology Department, Hôpital de la Timone, APHM, Aix-Marseille Université, Marseille, France; Aix Marseille Univ, INSERM, INRA, NORT, Marseille, France. 4. Centre Spécialisé de l'Obésité (CSO) PACA Ouest, France; Digestive Surgery Department, Hôpital Nord, APHM, Aix-Marseille Université, Marseille, France. 5. Centre Spécialisé de l'Obésité (CSO) de Nancy, Coordination nationale des CSO, France. 6. Endocrinology, Metabolic Diseases, and Nutrition Department, Pole ENDO, APHM, Aix-Marseille Université, Marseille, France; Centre Spécialisé de l'Obésité (CSO) PACA Ouest, France; Aix Marseille Univ, INSERM, INRA, NORT, Marseille, France. Electronic address: benedicte.gaborit@ap-hm.fr.
Abstract
BACKGROUND: Venous thromboembolism (VTE) is a leading cause of death in obese patients undergoing bariatric surgery (BS), but there is neither consensus nor high-level guidelines yet on VTE prophylaxis in this specific population. OBJECTIVE: We aimed to evaluate patterns of BS perioperative thromboprophylaxis practices. SETTING: French obesity specialized care centers (CSO), which are tertiary care referral hospitals for the most severe cases of obesity METHODS: A detailed questionnaire survey (11 opened, 15 closed questions) investigating their prophylactic schemes of anticoagulation (molecule, dose, weight-adjustment, duration, associated measures, follow-up) was sent to the 37 CSO. RESULTS: Completion rate was 92%. Over 90% of respondents indicated using low molecular weight heparin. Enoxaparin was the most commonly used molecule (89%), twice daily (71%), started mostly 6 hours after BS (74%), whereas fondaparinux (9%), dalteparin (6%), and tinzaparin (6%) were less often prescribed. Dosing varied significantly according to centers from 4000 to 12,000 IU/d, with the most commonly used dose being 8000 IU once daily, 83%, as well as treatment duration (1 week, 9%; 3 weeks, 47%). Half CSO adjusted low molecular weight heparin dose to weight. Biological monitoring was performed in 88%. Only 1 center followed systematically anti-Xa activity. Associated measures such as elastic stoking or intermittent pneumatic compression were used in 32% and 26%, respectively, and both were used in 39%. CONCLUSION: This study finds significant discrepancies in thromboprophylaxis practices in obese patients undergoing BS, particularly with respect to treatment duration and dose adjustment, highlighting the urgent need for improved implementation of existing clinical practice guidelines in this VTE high-risk population.
BACKGROUND:Venous thromboembolism (VTE) is a leading cause of death in obesepatients undergoing bariatric surgery (BS), but there is neither consensus nor high-level guidelines yet on VTE prophylaxis in this specific population. OBJECTIVE: We aimed to evaluate patterns of BS perioperative thromboprophylaxis practices. SETTING: French obesity specialized care centers (CSO), which are tertiary care referral hospitals for the most severe cases of obesity METHODS: A detailed questionnaire survey (11 opened, 15 closed questions) investigating their prophylactic schemes of anticoagulation (molecule, dose, weight-adjustment, duration, associated measures, follow-up) was sent to the 37 CSO. RESULTS: Completion rate was 92%. Over 90% of respondents indicated using low molecular weight heparin. Enoxaparin was the most commonly used molecule (89%), twice daily (71%), started mostly 6 hours after BS (74%), whereas fondaparinux (9%), dalteparin (6%), and tinzaparin (6%) were less often prescribed. Dosing varied significantly according to centers from 4000 to 12,000 IU/d, with the most commonly used dose being 8000 IU once daily, 83%, as well as treatment duration (1 week, 9%; 3 weeks, 47%). Half CSO adjusted low molecular weight heparin dose to weight. Biological monitoring was performed in 88%. Only 1 center followed systematically anti-Xa activity. Associated measures such as elastic stoking or intermittent pneumatic compression were used in 32% and 26%, respectively, and both were used in 39%. CONCLUSION: This study finds significant discrepancies in thromboprophylaxis practices in obesepatients undergoing BS, particularly with respect to treatment duration and dose adjustment, highlighting the urgent need for improved implementation of existing clinical practice guidelines in this VTE high-risk population.
Authors: Lee D Ying; Andrew J Duffy; Kurt E Roberts; Saber Ghiassi; Matthew O Hubbard; Geoffrey S Nadzam Journal: Obes Surg Date: 2019-06 Impact factor: 4.129
Authors: Erin B Fennern; Farhood Farjah; Judy Y Chen; Francys C Verdial; Sara B Cook; Erika M Wolff; Saurabh Khandelwal Journal: Surg Endosc Date: 2020-10-06 Impact factor: 4.584
Authors: Erik Stenberg; Luiz Fernando Dos Reis Falcão; Mary O'Kane; Ronald Liem; Dimitri J Pournaras; Paulina Salminen; Richard D Urman; Anupama Wadhwa; Ulf O Gustafsson; Anders Thorell Journal: World J Surg Date: 2022-01-04 Impact factor: 3.352